Evolution of the tissue selective estrogen complex (TSEC)

Journal of Cellular Physiology

Volumn 228, Issue 7, 2013, Pages 1423-1427

  Komm, Barry S ^a   Mirkin, Sebastian ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN RECEPTOR; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID HORMONE RECEPTOR BLOCKING AGENT; TISSUE SELECTIVE ESTROGEN COMPLEX; UNCLASSIFIED DRUG;

BONE; CENTRAL NERVOUS SYSTEM; CHEMICAL ANALYSIS; ENDOMETRIUM; GENE EXPRESSION; HORMONE ACTION; HUMAN; MAMMARY GLAND; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; TISSUE REACTION;

ANIMALS; BONE AND BONES; BREAST; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM; ENDOMETRIUM; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; GENE EXPRESSION; HUMANS; LIPIDS; MENOPAUSE; MICE; ORGAN SPECIFICITY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 84875517862     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24324     Document Type: Review

References (65)

1. Archer DF, Lobo RA, Pan K, Chines AA, Mirkin S. 2011. Safety and tolerability of bazedoxifene/conjugated estrogens in postmenopausal women: Findings from a 1-year, randomized, placebo- and active-controlled, phase 3 trial. Menopause 18: 1355-1356; abstract P-25.
2. Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR. 2005. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 105: 1063-1073.
3. Berrodin TJ, Chang KC, Komm BS, Freedman LP, Nagpal S. 2009. Differential biochemical and cellular actions of premarin estrogens: Distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol 23: 75-85.
4. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR. 1994. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93: 63-69.
5. Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. 2010. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: Insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 118: 117-124.
6. Cosman F, Lindsay R. 1999. Selective estrogen receptor modulators: Clinical spectrum. Endocr Rev 20: 418-434.
7. Crabtree JS, Peano BJ, Zhang X, Komm BS, Winneker RC, Harris HA. 2008. Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 287: 40-46.
8. Deroo BJ, Korach KS. 2006. Estrogen receptors and human disease. J Clin Invest 116: 561-570.
9. Ethun KF, Wood CE, Register TC, Cline JM, Appt SE, Clarkson TB. 2012. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause 19: 1242-1252.
10. Evans GL, Bryant HU, Magee DE, Turner RT. 1996. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia. Endocrinology 137: 4139-4144.
11. Gallagher JC, Lindsay R, Pan K, Mirkin S, Chines A. 2011. Effects of bazedoxifene/conjugated estrogens on bone mineral density and bone turnover markers in postmenopausal women: A double-blind, randomized, placebo- and active-controlled phase 3 study. J Bone Miner Res 26: S46; abstract 1133.
12. Gundlah C, Kohama SG, Mirkes SJ, Garyfallou VT, Urbanski HF, Bethea CL. 2000. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: Continued expression with hormone replacement. Brain Res Mol Brain Res 76: 191-204.
13. Hall JM, McDonnell DP. 1999. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578.
14. Harvey JA, Pinkerton JV, Pan K, Thompson JR, Ryan KA, Mirkin S, Chines AA. 2011. The effects of bazedoxifene/conjugated estrogens on breast density in postmenopausal women. Menopause 18: 1342; abstract S-1.
15. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M, Gustafsson JA. 2007. Estrogen receptors: How do they signal and what are their targets. Physiol Rev 87: 905-931.
16. Jordan VC, Morrow M. 1999. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20: 253-278.
17. Jordan VC, O'Malley BW. 2007. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 25: 5815-5824.
18. Jordan VC, Phelps E, Lindgren JU. 1987. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10: 31-35.
19. Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Silva-Jardine P, Thompson DD. 1998. Effects of CP-336, 156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139: 2068-2076.
20. Ke HZ, Chidsey-Frink KL, Simmons A, Thompson DD. 2000. Co-treatment of lasofoxifene (CP-336, 156) and estrogen inhibits estrogen's effect in the uterus but maintains the bone protective effects in ovariectomized rats [abstract]. J Bone Miner Res 15: S310.
21. Ke HZ, Brown TA, Thompson DD. 2002. Lasofoxifene (CP-336, 156), a novel selective estrogen receptor modulator, in preclinical studies. J Am Aging Assoc 25: 87-100.
22. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. 2004. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145: 1996-2005.
23. Kharode Y, Bodine PV, Miller CP, Lyttle CR, Komm BS. 2008. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 149: 6084-6091.
24. Komm BS. 2008. A new approach to menopausal therapy: The tissue selective estrogen complex. Reprod Sci 15: 984-992.
25. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. 2005. Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 146: 3999-4008.
26. Komm BS, Vlasseros F, Samadfam R, Chouinard L, Smith SY. 2011. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone 49: 376-386.
27. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
28. Kulak J, Jr., Fischer C, Komm B, Taylor HS. 2011. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology 152: 3226-3232.
29. Leitman DC, Paruthiyil S, Yuan C, Herber CB, Olshansky M, Tagliaferri M, Cohen I, Speed TP. 2012. Tissue-specific regulation of genes by estrogen receptors. Semin Reprod Med 30: 14-22.
30. Lerner LJ, Jordan VC. 1990. Development of antiestrogens and their use in breast cancer: Eighth Cain memorial award lecture. Cancer Res 50: 4177-4189.
31. Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. 2004. Hormone replacement therapy in postmenopausal women: Endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 3: CD000402.
32. Lewis-Wambi JS, Kim H, Curpan R, Grigg R, Sarker MA, Jordan VC. 2011. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol 80: 610-620.
33. Li H, Tu Z, An L, Qian Z, Achilefu S, Gu Y. 2012. Inhibitory effects of ERbeta on proliferation, invasion, and tumor formation of MCF-7 breast cancer cells-prognostication for the use of ERbeta-selective therapy. Pharm Biol 50: 839-849.
34. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. 2009. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 92: 1045-1052.
35. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, Constantine G. 2009. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 92: 1025-1038.
36. Loose-Mitchell DS, Stancel GM. 2001. Estrogens and progestins. In: Hardman JG, Limbird LE, Goodman Gilman A, editors. Goodman & Gilman's the pharmacological basis of therapeutics. New York, NY: McGraw-Hill. pp 1597-1634.
37. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL. 1992. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326: 852-856.
38. Matthews J, Gustafsson JA. 2003. Estrogen signaling: A subtle balance between ER alpha and ER beta. Mol Interv 3: 281-292.
39. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. 2006. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20: 534-543.
40. McDonnell DP, Wardell SE. 2010. The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer. Curr Opin Pharmacol 10: 620-628.
41. Mendelsohn ME, Karas RH. 1999. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
42. Mirkin S, Komm BS, Pan K, Chines AA. 2012a. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric DOI: 10.3109/13697137.2012.717994
43. Mirkin S, Ryan KA, Pan K, Chines AA, Lobo RA. 2012b. A pooled analysis of the effects of bazedoxifene/conjugated estrogens on lipid parameters from the selective estrogens, menopause, and response to therapy trials. Endocr Rev 33 (abstract SAT-30).
44. Norris JD, Paige LA, Christensen DJ, Chang CY, Huacani MR, Fan D, Hamilton PT, Fowlkes DM, McDonnell DP. 1999. Peptide antagonists of the human estrogen receptor. Science 285: 744-746.
45. North American Menopause Society. 2012. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 19: 257-271.
46. Oliva P, Roncoroni C, Radaelli E, Brunialti E, Rizzi N, de MM, Scanziani E, Piaggio G, Ciana P, Komm B, Maggi A. 2013. Global Profiling of TSEC proliferative potential by the use of a reporter mouse for proliferation. Reprod Sci 20: 119-128.
47. Ostlund H, Keller E, Hurd YL. 2003. Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann N Y Acad Sci 1007: 54-63.
48. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. 1997. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
49. Pal R, Chaturvedi R, Kamboj KK, Chowdhury SR, Dwivedi A. 2001. Estrogen receptors in rat bone: Their interaction with estrogen receptor modulators. Endocr Res 27: 283-291.
50. Parton M, Smith IE. 2008. Controversies in the management of patients with breast cancer: Adjuvant endocrine therapy in premenopausal women. J Clin Oncol 26: 745-752.
51. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. 2004. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64: 423-428.
52. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. 2009. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 150: 1897-1903.
53. Pelletier G, El-Alfy M. 2000. Immunocytochemical localization of estrogen receptors alpha and beta in the human reproductive organs. J Clin Endocrinol Metab 85: 4835-4840.
54. Pickar JH, Yeh I-T, Bachmann G, Speroff L. 2009. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 92: 1018-1024.
55. Pickar JH, MacNeil T, Ohleth K. 2010. SERMs: Progress and future perspectives. Maturitas 67: 129-138.
56. Pinkerton JV, Goldstein SR. 2010. Endometrial safety: A key hurdle for selective estrogen receptor modulators in development. Menopause 17: 642-653.
57. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. 2009. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: A randomized, controlled trial. Menopause 16: 1116-1124.
58. Powell E, Shanle E, Brinkman A, Li J, Keles S, Wisinski KB, Huang W, Xu W. 2012. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. PLoS ONE 7: e30993.
59. Song Y, Santen RJ, Wang JP, Yue W. 2012. Effects of the conjugated equine estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology 153: 5706-5715.
60. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. 2004. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: Distinct and common target genes for these receptors. Endocrinology 145: 3473-3486.
61. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. 2004. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101: 1566-1571.
62. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V. 1999. Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J 18: 4270-4279.
63. Vogelvang TE, van der Mooren MJ, Mijatovic V. 2004. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: Cardiovascular effects and clinical implications. Treat Endocrinol 3: 105-115.
64. Wardell SE, Kazmin D, McDonnell DP. 2012. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. Mol Endocrinol 26: 1235-1248.
65. Writing Group for the PEPI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273: 199-208.